US › Healthcare

Equillium Inc (EQ)

US · Healthcare · Biotechnology

$1.89+1.89%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.7M

EPS

$-0.04

EPS estimate

$-0.05

EPS came in at -0.04 against a street estimate of -0.05 — a beat of 20.0%.

Key statistics

Market cap

$133.8M

Forward P/E

1.5

P/B

2.39

Book value

$0.88

EPS (TTM)

$-0.09

52-week high

$3.54

52-week low

$0.76

50-day MA

$2.43

200-day MA

$2.02

Beta

1.80

Analyst view

Analysts rate Equillium Inc a hold (0 buy, 2 hold, 0 sell out of 2) with an average price target of $8.56.

Shareholding

Insiders

16.00%

Institutions

65.76%

Largest institutional holders

Fund	Stake
HHG PLC	10.24%
Decheng Capital LLC	7.01%
Affinity Asset Advisors, LLC	6.47%
ADAR1 Capital Management LLC	5.88%
Aberdeen Group PLC	5.73%
Woodline Partners LP	5.52%
RA Capital Management, LLC	4.88%
Vanguard Capital Management, LLC	2.81%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Equillium Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.